cyrilzakka/clinical-trials huggingface dataset:
Establishment and Application of Dementia Case Management Information System: A Preliminary Study

The purpose of this study is to develop and examine the preliminary effects of an information system for facilitating dementia case management in the home setting.

This study is the second phase of the project. The first year is the development stage of the information system. In the second year, the investigators will conduct a pilot study to examine the effectiveness of the case management information system.

The purpose of this study is to develop and examine the preliminary effects of an information system for facilitating dementia case management in the home setting. In the previous research (phase I), a mixed method was used to explore the content of case management and assess the needs of the information system.

This study is the second phase of the project. The first year is the development stage of the information system. Based on the data collected in the previous research (phase I), the content and method of dementia case management will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly. In the second year, the investigators will conduct a pilot study to examine the effectiveness of the case management information system.

Eligibility Criteria:
Inclusion Criteria:

* Dementia Case Managers:

  1. Be at least 20 years old and could communicate in Chinese or Taiwanese.
  2. Currently work for dementia center, dementia care center, or Community-Based Dementia Care Center in Taiwan.
* Dementia family caregivers:

  1. Be at least 20 years old and could communicate in Chinese or Taiwanese.
  2. Primary caregivers
  3. The people with dementia under care are diagnosed with dementia Clinical Dementia Rating(CDR) 0.5 or higher.
  4. Live in northern Taiwan(including Taipei, New Taipei, Taoyuan, and Hsinchu).

Exclusion Criteria:

* Dementia Case Managers:

No longer working for dementia center, dementia care center, or Community-Based Dementia Care Center in Taiwan.

* Dementia family caregivers:

The people with dementia under care live in a long-term care facility or nursing home.
Cricoid Pressure vs. Paralaryngeal Pressure to Prevent Regurgitation

Comparing the effects of ' Cricoid pressure' or 'Paralaryngeal pressure' during endotracheal intubation procedure.

Applying Cricoid pressure is widely used procedure to prevent gastric contents regurgitation during endotracheal intubation. To find out effectiveness external pressure is applied, the investigators will evaluate the relative position of esophagus and trachea. And also comparing the effects of Cricoid pressure and Paralaryngeal pressure during whole tracheal intubation procedures.

1. Confirm the relative positions between esophagus and trachea in awake patients by using ultrasonography.
2. Compare the effect of 'Cricoid pressure' and 'Paralaryngeal pressure' to esophageal opening during tracheal intubation procedure as below points.

1) Awake states. (Before sedation) 2) Anesthetized states. (After muscle relaxation) 3) During direct intubation procedure.

Eligibility Criteria:
Inclusion Criteria:

* Who would be scheduled any surgery under general anesthesia and agree with the purpose of the study

Exclusion Criteria:

* Diseases or anatomical abnormalities in the neck, larynx, pharynx or esophagus,
* Aspiration tendency
* Known or predicted difficult airway.
Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women

The study is to evaluate the accuracy of a test device called "PAMG-1" to see if a pregnant women has ruptured membranes in comparison to standardly used testing methods.

The study is to evaluate the accuracy of the PAMG-1 immunoassay in comparison to standard diagnostic methods for premature preterm rupture of membranes including the sterile speculum exam and the amniodye test as the gold standard.

The procedure includes the insertion of a swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip. Processing of this swab will be performed without further involvement of the study participant. The insertion of the swab is a one time procedure and is the only addition to any standard of care that would applied to the patient during their clinical evaluation at that time. Given the study group and both pregnant and non-pregnant controls, standard of care procedures will include a wide variety of obstetrical and/or gynecological (OB/Gyn) procedures including but not limited to a vaginal exams, sterile speculum exams (including pap smears), biopsies, and amniocentesis. The swab for the PAMG-1 immunoassay will be performed after other evaluations are performed. Medical records of the subject and (if applicable) her newborn infant will be reviewed for data pertaining to the study, including, but not limited to, maternal and fetal outcomes at the time of enrollment and after delivery and history of the present illness requiring an OB/Gyn evaluation. The study participants will not be asked to do anything in addition to what is expected for the swab and their clinical visit. The PAMG-1 immunoassay will be obtained during the subjects regularly scheduled clinic appointment or hospital visit. No follow appointments will be needed.

Eligibility Criteria:
Inclusion Criteria:

* women 18 to 50 years of age
* being seen at the University of Iowa Women's Healthcare Clinic

Exclusion Criteria:

* men
Implementation of a Standardized Tracheostomy Education Discharge Protocol

The purpose of this study is to identify and establish a safe and effective tracheostomy teaching protocol for caregivers. Results of this study will help in the development of a discharge protocol that allows for caregiver confidence and activation in tracheostomy care for patients.

This is a 3-phase, prospective controlled cohort study .

The first "pre-implementation" phase will include assessment of healthcare utilization costs of tracheostomy patients currently and nursing perspective on current caregiver tracheostomy knowledge.

The second "protocol" phase will include assessment of the necessity, acceptability, feasibility, fidelity, safety and effectiveness of a standardized pathway and assessment of the caregiver's activation.

The third "post-implementation" phase will involve assessment of post-implementation tracheostomy-related healthcare utilization costs and nursing perspective on caregiver tracheostomy knowledge.

Eligibility Criteria:
Inclusion Criteria:

Patient participants:

* Diagnosis of malignancy of the head and neck requiring reconstruction and temporary tracheostomy
* No previous record of tracheostomy
* Has an identified family caregiver who is willing to participate
* Has the tracheostomy in place for at least 10 days after discharge

Caregiver participants:

* Family member or friend, who is 18 years or older, of an adult patient described above
* Identified by the patient as his/her primary caregiver who is providing daily assistance

Exclusion Criteria:

* Patients who do not have a caregiver
* Caregivers who are illiterate.
* Caregivers with previous tracheostomy experience.
* Patients who are decannulated from tracheostomy prior to discharge.
* Patients discharged to a skilled nursing facility at the time of discharge.
* Patients who are tolerating continuous tracheostomy capping at time of discharge
DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer

A type of magnetic resonance imaging called diffusion weighted imaging (DWI) will be tested to define cancerous from non-cancerous lesions in the breast.

For this study, the investigators plan to evaluate DWI scans performed in women with breast lesions identified by conventional breast MRI. The investigators will determine whether an ADC threshold can be defined for distinguishing benign and malignant lesions on DWI, assess the difference in ADC cutoffs for mass and non-mass lesions, and investigate the potential improvement in accuracy using techniques such as nonzero minimum b-value (to remove perfusion effects in the ADC measures) and normalized ADC measures (to account for variations in water content and other factors).

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to provide written informed consent;
* 18 years of age or older;
* Successful completion of breast MR examination with DWI required by protocol;
* Undiagnosed breast lesion (BI-RADS 3, 4, or 5) identified on MRI. The BI-RADS assessment must refer to a focal finding within the breast (i.e. mass, non-mass, or focus) as opposed to diffuse processes (e.g. background parenchymal enhancement, skin thickening) or lesions outside the subcutaneous breast (e.g. axillary lymph nodes, focal skin lesions, osseous lesions, etc.).

Exclusion Criteria:

* Participants with current or recent history (within 6 months prior to the MRI) of chemotherapy for cancer;
* Neoadjuvant chemotherapy between MRI and confirmation of lesion outcome (study lesions must be biopsied prior to undergoing any chemotherapy);
* Pregnant (if a female is of childbearing potential - defined as a pre-menopausal female capable of becoming pregnant - confirmation of pregnancy status per the site's standard of practice should be done prior to MRI);
* Unwilling or not suitable to undergo MRI or use the contrast agent gadolinium.
Preoperative Estimation of Microvascular Invasion in Hepatocellular Carcinoma

Presence of microvascular invasion can be estimated preoperatively, by some clinical imaging features such as patient characteristics, serum biomarkers and radiological features. Contrast-enhanced ultrasonography (CEUS) and contrast-enhanced computed tomography (CECT) are routine preoperative conventional examinations for hepatocellular carcinoma (HCC) patients in China. Combining features of CEUS, CECT and clinical factors may improve preoperative MVI assessment. The purpose of this study is to construct a nomogram for preoperative MVI risk estimation with these possible factors.


Eligibility Criteria:
Inclusion Criteria:

* Asian patients aged 18～80 years old;
* With no preoperative anti-cancer treatment;
* Scheduled for radical liver resection;
* With both CEUS and CECT performed in 4 weeks before surgery;
* Postoperative histologically confirmed HCC;
* With sufficient surgical specimen for MVI detection (surgical margin ≥1cm);

Exclusion Criteria:

* Recurrent HCC or combined hepatocellular-cholangiocarcinoma;
* With extra-hepatic metastasis or macrovascular invasion;
* With incomplete clinical and imaging data;
* Non-radical resection;
CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.


Eligibility Criteria:
Inclusion Criteria:

* 1. In-patients with acute coronary syndrome to undergo PCI 2. Complete revascularization during the index hospitalization 3. Written informed consent

Exclusion Criteria:

* 1. Periprocedural complications (coronary artery dissection, perforation, myocardial infarction, stroke, death) 2. Planned coronary revascularization at discharge 3. Patients with severe chronic disease (uremia, liver cirrhosis, COPD (chronic obstructive pulmonary disease) 4. Abnormal blood counts caused by hematological diseases 5. Diagnosed malignancy
Study of Adjuvant Radiochemotherapy for Gastric Cancer

In 1991, the South West Oncology Group (SWOG) conducted a randomized study of adjuvant chemotherapy (5-fluorouracil and folinic acid) with concurrent radiation (4500 cGy/25 fractions) versus surgery alone for patients with completely resected gastric carcinoma.

This landmark study showed the benefit of adjuvant treatment for gastric cancer and radically changed the treatment of this disease. However, the resulting standard treatment has severe acute toxicity, and despite this advance, 50% of patients still die of gastric cancer. The investigators hope to develop a modified protocol using active chemotherapy agents, but with reduced acute toxicity. Such an approach could ultimately be studied against the current SWOG approach to determine whether or not the addition of cisplatinum improves efficacy.

Patients who decide to participate in the study will receive a chemotherapy drug called 5-Fluorouracil (5FU)through an intravenous catheter continuously over 12 weeks. Patients will not be admitted to hospital to receive the chemotherapy but will need to wear a waist pack to carry a small pump that will deliver the medication. They will however need to make regular visits to have their medication bags changed. Patients will also receive Cisplatin intravenously every 2 weeks for 4 doses. In addition, patients will also receive radiation to their stomach, lymph nodes, and the area where they had their surgery. This study also comprise of a questionnaire for us to see how patient's cancer and treatment is affecting their quality of life. Patients will have regular follow-up by their physicians.


Eligibility Criteria:
Inclusion Criteria:

* R0 resection (no microscopic residual) of adenocarcinoma of stomach or gastroesophageal (GE) junction, prior to starting chemotherapy and radiation
* Tumor must not extend more than 2 cm along the esophagus; bulk of the tumor must be in the stomach.
* Adequate pre-operative cross-sectional imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\])
* International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) Stage IB - IV, excluding patients with metastatic disease (T1N1, T2N0 to T4N1, N2, and any T, N3). T2N0 eligible only if disease extends beyond muscularis propria.
* No previous abdominal radiotherapy or contraindication to radiotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status \< 2
* Adequate major organ function
* Nutritional intake of at least 1500 calories per day at nutrition assessment
* Treatment started within 20-90 days post-op of surgery date.
* Informed consent

Exclusion Criteria:

* Less than 70 years of age
Prostaglandin Analog Eyelash Serum and Ocular Surface Health: A Prospective Study

This prospective interventional study investigates the effects of a prostaglandin analog-based eyelash serum on ocular surface integrity, tear film stability, and eyelash growth over six weeks. Nineteen healthy female participants applied the serum daily, with clinical assessments performed at baseline and post-treatment. The study adhered to ethical guidelines, and parameters such as tear film stability, tear volume, ocular hyperemia, and eyelash characteristics were evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Female individuals aged 18 to 30 years.
* Corrected distance visual acuity (CDVA) of 0.10 LogMAR or better in both eyes.
* Fitzpatrick skin type III or lower.
* No active dermatological conditions affecting the periocular area.
* Regular use of cosmetic products (e.g., mascara, eyeliner, or eyeshadow) with no history of intolerance.
* Willingness and ability to follow the serum application protocol for six weeks.

Exclusion Criteria:

* History or diagnosis of dry eye disease or other ocular surface disorders.
* Previous ocular surgery, trauma, or systemic conditions affecting ocular surface function.
* Use of topical or systemic medications that could impact tear film stability.
* Documented hypersensitivity or allergic reactions to cosmetic or ophthalmic products.
* Presence of eyelid disorders that could interfere with eyelash growth (e.g., blepharitis, trichiasis).
* Use of growth-enhancing serums within the past three months.
* Pregnancy or breastfeeding at the time of enrollment.
Continous Renal Replacement Therapy With the CARPEDIEM® in a French National Cohort of 25 Neonates and Small Infants

Historically, CKRT and hemodialysis were performed in small infants and newborns with devices developed for adults with high rates of complications and mortality.

We aim to retrospectively report the first multicenter French experience of CARPEDIEM® use and evaluate the efficacy, feasibility, outcomes, and technical considerations of this new device in a population of neonates and small infant. Compared to adult's device continuous renal replacement therapy with an adapted machine allowed successful blood purification without severe complications even in low birth weight neonates.


Eligibility Criteria:
Inclusion criteria:

* Children and neonates including premature and low birth weight neonates
* Have a diagnosis of acute kidney injury, end stage renal disease, metabolic disease, electrolyte abnormality
* Require renal replacement therapy

Exclusion Criteria:

-Renal replacement therapy with another device than Carpediem machine
Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection

The purpose of the trial is to evaluate the effect of Djulis-Buckwheat drink on cardiovascular protection after ingesting for 8 weeks. In addition, the correlation between the supplement and the cardiovascular disease-related gene expression is evaluated. The results will be used for the application of functional products for cardiovascular protection.

Ninety subjects (age 30\~65) with Prehypertension or Hypertension stage 1 will be included and randomly allocated into 3 groups: Placebo, Djulis-Buckwheat and Buckwheat. The subjects will take sample (100 ml/day) for 8 weeks. Blood pressure will be measured on week 0, 1, 2, 4, 6 and 8. The blood biochemical parameters and gene expression analysis will be examined on week 2, 4, 6, 8 and 10 (the follow up).


Eligibility Criteria:
Inclusion Criteria:

* Systolic blood pressure 121-159 mmHg or Diastolic blood pressure 81-99 mmHg
* Age: 30-65

Exclusion Criteria:

* Have diagnosed and documented critical illness(NHI specification)
* Had emergency record or admission note in the past three months
* Not be pregnant or breast-feeding a child
Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour

Preterm birth is the leading cause of perinatal mortality and morbidity. According to WHO, 15 million children are born prematurely (gestational age \< 37 weeks) in the world each year while 7% of them die because of complications associated with prematurity. Despite constant improvement of obstetrical care, the number of preterm births has increased over the last decades and prematurity is still the most frequent cause of prenatal hospitalization in industrialized countries.

The American College of Obstetricians and Gynecologists as well as the Royal College of Obstetricians and Gynaecologists recommend nifedipine as a first-line tocolytic in case of acute threatened preterm labour. Clinical experience show however an important variability in treatment response among pregnant women. In spite of its large use in obstetrics as a tocolytic agent, nifedipine is prescribed off-label. As a consequence no international consensus on optimal dose schedule has so far been proposed.

Small sample size and heterogeneousness of tocolysis administration protocols make it difficult to compare the little data available on the pharmacokinetics of nifedipine in pregnant women. Nevertheless an important interindividual variability in concentrations has been identified (CV=12-76%) but very few studies have investigated the possible reasons of this variability in pregnant women. Genetic and environmental factors involved in drug distribution and metabolism (e.g. enzymatic activity, CYP 3A5 genotype) might partially explain variability in drug levels and therefore differences in treatment response.

The goal of this study is to quantify the variability in nifedipine pharmacokinetics and identify potential genetic and non-genetic sources of variability in nifedipine pharmacokinetics in pregnant women. The relationship between concentration and treatment response will be evaluated and will serve to propose optimal dosage regimen to improve efficacy and reduce side effects associated with this treatment.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant women under nifedipine treatment for acute threatened preterm labour
* Hospitalization for this condition in the maternity of the University Hospital of Lausanne (CHUV)
* Gestational age of 20-34 weeks
* Signed informed consent

Exclusion Criteria:

* Patient \< 18 years
* Contraindication to tocolysis for clinical reasons (e.g. severe pre-eclampsia, chorioamnionitis, placental anomaly, letal fetal anomaly, important intrauterine growth restriction) or current labour
* Contraindication to nifedipine
* Severe renal or hepatic impairment
* Fever \> 37.5°C
* Incapacity of communication
Effect of a 'Rapid-Return-to-work Program' in Mild Mental Disorders.

This study is a pragmatic randomized controlled trial (RCT) evaluating the effect of brief versus short psychotherapy in subjects with substantial mental complaints.

Running evaluations of the brief intervention (BI) at our outpatient clinic preceding to this study had given us the impression that the patients obtained a more active coping style towards their health problems with consequential enhanced work participation (WP). These evaluations, in addition to our experiences in BI for low back pain (LBP) has generated the current hypothesis of this study towards WP. Yet, the sustainability of WP and long-term effects on mental health remained questionable. In this pragmatic RCT the objective was to compare brief psychotherapy with focus on normalization and coping (Brief-PsT) with short-term psychotherapy of standard duration with more extended focus (Short-PsT), as otherwise used at the Mental Health services. The primary aim of this study was to assess differences in effect on WP and the secondary aim was to assess differences in clinical response. The investigators hypothesized that in the short term, Brief-PsT could facilitate or sustain WP in a superior fashion to Short-PsT in persons who are on, or at risk of sick leave due to mental health problems. Although the investigators expected a substantial long-term rate of clinical recovery and reduction in mental health-related symptoms in both groups, the investigators had no specific hypothesis regarding the extent and direction of possible group differences in these clinical measurements.

Eligibility Criteria:
Inclusion Criteria:

* 'mental complaints' was the main reason for referral to the outpatient clinic
* employed and on or at risk of sick leave

Exclusion Criteria:

* acute or severe pathology that required greater input than the clinic could offer,
* Sick-leave had \> 9 months during the preceding 2 years